TYRX announces its Fully Resorbable AIGISRx R Antibacterial Envelope for use with pacemakers and implantable cardioverter defibrillators (ICDs) has received FDA clearance. IGISRx R is a fully bioresorbable, antibacterial mesh envelope, intended to hold CIEDs securely in place and provide a stable environment when implanted in the body. AIGISRx R contains antimicrobial agents which are released locally into the tissue, to help reduce surgical site infection associated with CIED implantation. Multiple studies have shown that in patients at high-risk for device infection, CIED implantation with the AIGISRx Antibacterial Envelope significantly reduced device infections by 70% – 100%.

 For more information, visit www.TYRX.com